271 related articles for article (PubMed ID: 26152149)
21. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
Miles D; Jumbe NL; Lacy S; Nguyen L
Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
[TBL] [Abstract][Full Text] [Related]
22. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
Hellerstedt BA; Vogelzang NJ; Kluger HM; Yasenchak CA; Aftab DT; Ramies DA; Gordon MS; Lara P
Clin Lung Cancer; 2019 Mar; 20(2):74-81.e1. PubMed ID: 30528315
[TBL] [Abstract][Full Text] [Related]
23. Cabozantinib in genitourinary malignancies.
Zhang T; Park SE; Hong C; George DJ
Future Oncol; 2017 Apr; 13(8):755-765. PubMed ID: 27842445
[TBL] [Abstract][Full Text] [Related]
24. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.
Viola D; Cappagli V; Elisei R
Future Oncol; 2013 Aug; 9(8):1083-92. PubMed ID: 23902240
[TBL] [Abstract][Full Text] [Related]
25. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Brose MS; Robinson BG; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Sen S; Oliver JW; Banerjee K; Keam B; Capdevila J
Cancer; 2022 Dec; 128(24):4203-4212. PubMed ID: 36259380
[TBL] [Abstract][Full Text] [Related]
26. Novel therapies for thyroid cancer.
Krajewska J; Jarzab B
Expert Opin Pharmacother; 2014 Dec; 15(18):2641-52. PubMed ID: 25318585
[TBL] [Abstract][Full Text] [Related]
27. Cabozantinib approved for advanced medullary thyroid cancer.
Traynor K
Am J Health Syst Pharm; 2013 Jan; 70(2):88. PubMed ID: 23292257
[No Abstract] [Full Text] [Related]
28. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F
BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169
[TBL] [Abstract][Full Text] [Related]
29. Cabozantinib as an emerging treatment for sarcoma.
Schöffski P; Blay JY; Ray-Coquard I
Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
[TBL] [Abstract][Full Text] [Related]
30. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
31. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Schöffski P; Gordon M; Smith DC; Kurzrock R; Daud A; Vogelzang NJ; Lee Y; Scheffold C; Shapiro GI
Eur J Cancer; 2017 Nov; 86():296-304. PubMed ID: 29059635
[TBL] [Abstract][Full Text] [Related]
32. Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.
Rajabi S; Hedayati M
Mol Diagn Ther; 2017 Dec; 21(6):607-620. PubMed ID: 28698976
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Drilon A; Rekhtman N; Arcila M; Wang L; Ni A; Albano M; Van Voorthuysen M; Somwar R; Smith RS; Montecalvo J; Plodkowski A; Ginsberg MS; Riely GJ; Rudin CM; Ladanyi M; Kris MG
Lancet Oncol; 2016 Dec; 17(12):1653-1660. PubMed ID: 27825636
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.
Nokihara H; Nishio M; Yamamoto N; Fujiwara Y; Horinouchi H; Kanda S; Horiike A; Ohyanagi F; Yanagitani N; Nguyen L; Yaron Y; Borgman A; Tamura T
Clin Lung Cancer; 2019 May; 20(3):e317-e328. PubMed ID: 30718102
[TBL] [Abstract][Full Text] [Related]
35. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
36. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.
Lacy SA; Miles DR; Nguyen LT
Clin Pharmacokinet; 2017 May; 56(5):477-491. PubMed ID: 27734291
[TBL] [Abstract][Full Text] [Related]
37. cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.
Prescrire Int; 2016 Jan; 25(167):11-3. PubMed ID: 26942253
[TBL] [Abstract][Full Text] [Related]
38. Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI. J Clin Oncol 2013;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.
Trump DL
Urol Oncol; 2013 Nov; 31(8):1848. PubMed ID: 24210087
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer.
Karras S; Pontikides N; Krassas GE
Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):507-15. PubMed ID: 23488614
[TBL] [Abstract][Full Text] [Related]
40. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.
Capdevila J; Klochikhin A; Leboulleux S; Isaev P; Badiu C; Robinson B; Hughes BGM; Keam B; Parnis F; Elisei R; Gajate P; Gan HK; Kapiteijn E; Locati L; Mangeshkar M; Faoro L; Krajewska J; Jarzab B
Thyroid; 2022 May; 32(5):515-524. PubMed ID: 35403447
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
